Xinrong Granules
Function and Efficacy
1. Xinrong significantly improves the ischemic and hypoxic state of rat myocardial ischemic and hypoxic necrosis caused by isoproterenol, reduces myocardial oxygen consumption, and significantly alleviates myocardial necrosis. 2. Xinrong has a significant protective effect on the damage caused by isoproterenol to rat and neonatal myocardial cells cultured in vitro. 3. Xinrong has a certain improvement on the electrocardiogram of myocardial obstructive ischemic injury caused by coronary artery ligation in rats, and has a significant effect on reducing the increased activity of plasma lactate dehydrogenase (LDH) and creatine phosphokinase (CPK) in rats and the increased content of plasma free fatty acids (FFA). 4. Xinrong can significantly reduce the TBA value in plasma of rat J myocardial necrosis caused by isoproterenol, play an anti-lipid peroxidation role, and significantly reduce the activity of enzymes such as EBDH and CPK in plasma. 5 The SWANGANZ floating catheter experiment was used to observe the acute hemodynamic effects of Xinrong on patients with congestive heart failure. The results showed that this product can reduce pulmonary artery pressure (MPAP), pulmonary wedge pressure (PCWP), and increase cardiac index (C1). 6 It can increase the activity of superoxide dismutase (SOD) in red blood cells of patients with myocardial injury and reduce the content of lipid peroxide (LPO) in plasma.
Ingredients
Astragalus, Rehmannia root, Ophiopogon japonicus, Schisandra chinensis, Red Peony Root, Cinnamon Twig
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Anise oilIngredients |
Xinrong improves myocardial ischemia-hypoxic necrosis in rats induced by isoproterenol, reduces myocardial oxygen consumption, and alleviates myocardial necrosis; it has a protective effect on myocardial cell damage in rats and neonates; it improves the electrocardiogram of myocardial obstructive ischemia injury in rats after coronary artery ligation; it reduces the TBA value in plasma and resists lipid peroxidation; it reduces the activity of enzymes such as hydroxybutyrate dehydrogenase (CPK) in plasma; it reduces pulmonary artery pressure (MPAP) and pulmonary wedge pressure (PCWP), and increases the cardiac index (C1); it increases the activity of erythrocyte superoxide dismutase (SOD), and reduces the content of lipid peroxide (LPO) in plasma. More |
8007-70-3 | 10 |
Appearance
This product is brown to brown-red granules; it tastes sweet and slightly bitter.
Usage and Dosage
Oral administration. 5 capsules at a time (or one bag at a time, or 2 sticks at a time), 3 times a day, for 6 weeks or as directed by your doctor.
Adverse Reactions
Dry mouth, nausea, and bowel movements may occur occasionally but generally do not affect treatment.
Precautions
Not yet clear.
Drug Interactions
Drug interactions may occur if used with other drugs. Please consult your doctor or pharmacist for details.
Storage
Sealed in a cool, dry place.
Packaging Specification
10g per bag
Validity Period
36 months
Manufacturer
Anhui Joyfar Pharmaceutical Co., Ltd.
-
Founded in:
1997-12-08 -
Address:
Anhui Bozhou Economic Development Zone -
Tax NO.:
91341600151945984H -
Registered Funds:
45 million yuan -
Website:
-
Email: